✦ LIBER ✦

The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions

✍ Scribed by Fiona CHIONH; Gillian MITCHELL; Geoffrey J LINDEMAN; Michael FRIEDLANDER; Clare L SCOTT

Book ID: 111318912
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 312 KB
Volume: 7
Category: Article
ISSN: 1743-7555
DOI: 10.1111/j.1743-7563.2011.01430.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Effect of Poly (Adenosine Diphosphat

The Effect of Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors on Biochemical Changes in Testicular Ischemia-Reperfusion Injury

✍ BOZLU, M; ESKANDARI, G; CAYAN, S; CANPOLAT, B; AKBAY, E; ATIK, U 📂 Article 📅 2003 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 70 KB

Heat shock protein 90 inhibitors in the

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

✍ Jhaveri, Komal; Ochiana, Stefan O; Dunphy, Mark PS; Gerecitano, John F; Corben, 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 829 KB

189 Preclinical activity of the poly (AD

189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

✍ N. Nechiporchik; K. Lieb; L. Marquette; L. Polin; G.J. Peters; A. Chen; S.P. Eth 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Current Status and Future Directions of

Current Status and Future Directions of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Ovarian Cancer

✍ Helm, C. William 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Somatic Mutations in BRCA1 and BRCA2 Cou

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

✍ Hennessy, B. T. J.; Timms, K. M.; Carey, M. S.; Gutin, A.; Meyer, L. A.; Flake, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 182 KB

First in human trial of the poly(ADP)-ri

First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers

✍ R. Wenham; G. Wilding; R. Baird; L. Sun; C. Toniatti; M. Stroh; C. Carpenter; J. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 71 KB